# ASC4FIRST (NCT04971226)

> A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

No report yet. It can be ordered.

- Drugs tested: asciminib
- Indication: newly diagnosed Ph+ chronic-phase chronic myeloid leukemia

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04971226
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Novartis Pharmaceuticals
- Conditions: Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
- Interventions: Imatinib; Nilotinib; Bosutinib; Dasatinib; Asciminib
- Enrollment: 405
- Primary outcome: Percentage of Participants With Major Molecular Response (MMR) at Week 48 - Ascimimib vs. Investigator Selected TKI
- Primary outcome: Percentage of Participants With Major Molecular Response (MMR) at Week 48 - Asciminib (Imatinib Stratum) vs Investigator Selected TKI (Imatinib Stratum)

## Indexed commentary on ASC4FIRST so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 35
- YouTube: 19
- Podcasts: 16
- X videos: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=asc4first-nct04971226

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04971226", "email": "<work email>"}; the inbox owner confirms by the emailed link.